DSGN241220P2500
- 0.00
- 0.000.00%
Design Therapeutics Newsroom
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Design Therapeutics Analyst Ratings
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Buy Rating Justified by Design Therapeutics' Innovative Pipeline and Solid Financials
Design Therapeutics Analyst Ratings
Hold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program Updates
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics (DSGN) Gets a Hold From Piper Sandler
Hold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial Uncertainties
Design Therapeutics Analyst Ratings
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk
SVB Leerink Downgrades Design Therapeutics to Market Perform, Announces $6 Price Target
Design Therapeutics Analyst Ratings
RBC Downgrades Design Therapeutics to Sector Perform From Outperform, Cuts Price Target to $7 From $23 Amid 'Limited Near-Term Catalysts,' Keeps Speculative Risk
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)